Juvena Therapeutics
Juvena Therapeutics: A biopharmaceutical platform for novel protein-based therapeutics discovery.
- 11
- Company
- Redwood City, CA, USUnited States
Juvena Therapeutics: A biopharmaceutical platform for novel protein-based therapeutics discovery.
juvenatherapeutics.comCrawled Oct 15, 2026
Press releases from Juvena Therapeutics, the founding research behind JuvNET, and the company's posters and presentations.
Join Juvena Therapeutics in Redwood City, California, a clinical-stage biotech decoding the human secretome into regenerative medicines. Open roles and general inquiries.
Contact Juvena Therapeutics: partnering, investor and media inquiries, clinical study questions, and careers. 640 Galveston Drive, Redwood City, CA 94063.
Juvena Therapeutics engineers proteins naturally secreted by human stem cells into regenerative medicines. JUV-161 is an investigational medicine designed to restore IGF signaling and support muscle protein synthesis, function and metabolism.
Juvena Therapeutics names Julie Anne Smith as Chief Executive Officer and board member. She joins the clinical-stage biotech firm specializing in AI-driven regenerative biologics for restoring tissue function. Smith has over two decades of experience leading biopharmaceutical companies focused on rare diseases, neuromuscular disorders, and autoimmune therapies.
Aug 2026Yahoo FinanceNews article
Juvena secures **$33.5 million** in funding to accelerate the development of regenerative biologics targeting tissue restoration. The company prepares for expanded clinical trials while co-founder **Hanadie Yousef** steps down as CEO. Juvena focuses on therapies designed to repair damaged tissues through advanced biologic treatments.
Jan 2026Longevity.TechnologyNews article
Juvena Therapeutics partners with Lilly to leverage its AI platform, which maps the therapeutic potential of secreted proteins, aiming to develop treatments for muscle health. Lilly will use Juvena’s technology to identify new drug targets in this area. The collaboration focuses on addressing muscle-related conditions through AI-driven protein analysis.
Jun 2025GlobeNewswireNews article
Juvena Therapeutics begins the first human clinical trial of **JUV-161**, a novel muscle-regenerating biologic targeting **myopathies**, including **Myotonic Dystrophy Type 1**. The therapy was developed using proprietary discovery methods. The trial marks a key step in evaluating its safety and potential efficacy in treating degenerative muscle diseases.
May 2025GlobeNewswireNews article